Cardioprotection in the ESRD Population: How Do We Get There?

Area of Science:

• Nephrology
• Cardiology
• Public Health

Background:

• End-stage renal disease (ESRD) patients face a significantly elevated risk of cardiovascular mortality, approximately 30 times higher than the general population.
• Hyperlipidemia affects a substantial portion (around 30%) of ESRD patients, further increasing cardiovascular risk.
• Guidelines recommend proactive cardiovascular disease prevention and treatment in ESRD populations.

Purpose of the Study:

• To assess the utilization of key cardioprotective medications in patients with end-stage renal disease (ESRD).
• To compare cardioprotective drug prescribing patterns between ESRD patients and a non-ESRD population.
• To identify barriers to effective cardiovascular disease management in dialysis facilities.

Main Methods:

• A quality improvement project involving 28 dialysis facilities in Ohio.
• Chart abstraction to collect data on the use of angiotensin-converting enzyme inhibitors (ACE-I), angiotensin receptor blockers (ARB), beta-blockers, aspirin, and statins (HMG-CoA reductase inhibitors).
• Comparison of prescribing data with Ohio hospital discharge data for non-ESRD patients.

Main Results:

• ESRD patients showed lower rates of ACE-I use (27% vs. 75.7%) for heart failure and beta-blocker use (34.8% vs. 68.0%) post-myocardial infarction (MI) compared to non-ESRD patients.
• Aspirin use in ESRD patients with prior MI was 52.8%, significantly lower than the 88% in non-ESRD patients.
• Only 17.3% of ESRD patients were prescribed statins, despite hyperlipidemia prevalence of 30-50%.

Conclusions:

• Cardioprotective drug utilization is notably lower in Medicare ESRD patients compared to their non-dialysis counterparts.
• Fragmentation of healthcare, communication issues, and infrastructure deficits impede the implementation of cardioprotective strategies in ESRD care.
• Addressing these systemic issues is crucial to improving cardiovascular outcomes for ESRD patients.